- Home
- NTIP vs LGVN Comparison
NTIP vs LGVN Comparison
Compare NTIP & LGVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTIP
- LGVN
- Stock Information
- Founded
- NTIP 1990
- LGVN 2014
- Country
- NTIP United States
- LGVN United States
- Employees
- NTIP N/A
- LGVN N/A
- Industry
- NTIP Multi-Sector Companies
- LGVN Medicinal Chemicals and Botanical Products
- Sector
- NTIP Miscellaneous
- LGVN Health Care
- Exchange
- NTIP Nasdaq
- LGVN Nasdaq
- Market Cap
- NTIP 29.5M
- LGVN 28.4M
- IPO Year
- NTIP 1998
- LGVN 2021
- Fundamental
- Price
- NTIP $1.29
- LGVN $1.65
- Analyst Decision
- NTIP
- LGVN Strong Buy
- Analyst Count
- NTIP 0
- LGVN 3
- Target Price
- NTIP N/A
- LGVN $8.67
- AVG Volume (30 Days)
- NTIP 17.9K
- LGVN 319.6K
- Earning Date
- NTIP 10-24-2024
- LGVN 11-12-2024
- Dividend Yield
- NTIP 7.58%
- LGVN N/A
- EPS Growth
- NTIP N/A
- LGVN N/A
- EPS
- NTIP N/A
- LGVN N/A
- Revenue
- NTIP $1,881,000.00
- LGVN $1,852,000.00
- Revenue This Year
- NTIP N/A
- LGVN $161.78
- Revenue Next Year
- NTIP N/A
- LGVN $40.89
- P/E Ratio
- NTIP N/A
- LGVN N/A
- Revenue Growth
- NTIP 129.39
- LGVN 141.46
- 52 Week Low
- NTIP $1.24
- LGVN $0.77
- 52 Week High
- NTIP $2.25
- LGVN $21.30
- Technical
- Relative Strength Index (RSI)
- NTIP 45.22
- LGVN 31.55
- Support Level
- NTIP $1.25
- LGVN $1.80
- Resistance Level
- NTIP $1.37
- LGVN $2.15
- Average True Range (ATR)
- NTIP 0.05
- LGVN 0.13
- MACD
- NTIP -0.00
- LGVN -0.03
- Stochastic Oscillator
- NTIP 33.33
- LGVN 0.00
About NTIP Network-1 Technologies Inc.
Network-1 Technologies Inc is involved in the business of the development, licensing, and protection of intellectual property rights. The company's current plan includes continuing to pursue licensing opportunities for its intellectual property assets.
About LGVN Longeveron Inc.
Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.